Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?
Over the past decade, an increasing number of oncology medicines with indications for multiple cancer types have been delivering benefits to patients. To ensure these products reach patients, pricing and reimbursement systems have had to adapt to address the value assessment, time-to-access, afforda...
Saved in:
| Main Authors: | Hannah Armstrong, Angelina Petrova, Tim Wilsdon, Henriette Homoki, Alexander Roediger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2001-6689/13/1/2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights from veterinary models for advancing oncolytic virotherapy through comparative oncology
by: Almohanad A. Alkayyal
Published: (2025-05-01) -
Cardiotoxicity of genetic engineered biological therapy in immuno-mediated and oncological diseases
by: V. A. Akhmedov, et al.
Published: (2024-04-01) -
Monocytes and cancer: promising role as a diagnostic marker and application in therapy
by: M. R. Patysheva, et al.
Published: (2019-05-01) -
The principles of oncological alertness at the outpatient therapeutic stage
by: A. S. Sycheva, et al.
Published: (2021-09-01) -
Abeloff's Clinical Oncology /
by: Niederhuber, John E.
Published: (2014)